A case of treatment-resistant membranous nephropathy associated with graft versus host disease successfully treated with daratumumab.
Benoit, SW; Khandelwal, P; Grimley, MS.
Pediatric Transplantation.
2022;
26.
Scheduled administration of virus-specific T cells for viral prophylaxis after pediatric allogeneic stem cell transplant.
Rubinstein, JD; Lutzko, C; Leemhuis, T; Zhu, X; Pham, G; Ray, L; Thomas, S; Dourson, C; Wilhelm, J; Lane, A; et al.
Blood Advances.
2022;
6:2897-2907.
Granulocyte Colony-Stimulating Factor Is Safe and Well Tolerated following Allogeneic Transplantation in Patients with Sickle Cell Disease.
Shah, NC; Bhoopatiraju, S; Abraham, A; Anderson, E; Andreansky, M; Bhatia, M; Chaudhury, S; Cuvelier, GD E; Godder, K; Grimley, M; et al.
Transplantation and cellular therapy.
2022;
28:174.e1-174.e5.
Abatacept for GVHD prophylaxis can reduce racial disparities by abrogating the impact of mismatching in unrelated donor stem cell transplantation.
Qayed, M; Watkins, B; Gillespie, S; Bratrude, B; Betz, K; Choi, SW; Davis, J; Duncan, C; Giller, R; Grimley, M; et al.
Blood Advances.
2022;
6:746-749.
Ruxolitinib for the Treatment of Chronic GVHD and Overlap Syndrome in Children and Young Adults.
Wang, YZ M; Teusink-Cross, A; Elborai, Y; Krupski, MC; Nelson, AS; Grimley, MS; Flannery, A; Mehta, PA; Bleesing, JJ; Chandra, S; et al.
Transplantation.
2022;
106:412-419.
Off-the-Shelf Third-Party Virus-Specific T Cell Therapy to Treat JC Polyomavirus Infection in Hematopoietic Stem Cell Transplantation Recipients.
Rubinstein, JD; Jodele, S; Heyenbruch, D; Wilhelm, J; Thomas, S; Lutzko, C; Zhu, X; Leemhuis, T; Cancelas, JA; Keller, M; et al.
Transplantation and cellular therapy.
2022;
28:116.e1-116.e7.
Early stool microbiome and metabolome signatures in pediatric patients undergoing allogeneic hematopoietic cell transplantation.
Elgarten, CW; Tanes, C; Lee, JJ; Danziger-Isakov, LA; Grimley, MS; Green, M; Michaels, MG; Barnum, JL; Ardura, MI; Auletta, JJ; et al.
Pediatric Blood and Cancer.
2022;
69.
Case Report: Fatal Complications of BK Virus-Hemorrhagic Cystitis and Severe Cytokine Release Syndrome Following BK Virus-Specific T-Cells.
Holland, EM; Gonzalez, C; Levy, E; Valera, VA; Chalfin, H; Klicka-Skeels, J; Yates, B; Kleiner, DE; Hadigan, C; Dave, H; et al.
Frontiers in Immunology.
2021;
12.
Virus-specific T cells for adenovirus infection after stem cell transplantation are highly effective and class II HLA restricted.
Rubinstein, JD; Zhu, X; Leemhuis, T; Pham, G; Ray, L; Emberesh, S; Jodele, S; Thomas, S; Cancelas, JA; Bollard, CM; et al.
Blood Advances.
2021;
5:3309-3321.
Phase II Trial of Costimulation Blockade With Abatacept for Prevention of Acute GVHD.
Watkins, B; Qayed, M; McCracken, C; Bratrude, B; Betz, K; Suessmuth, Y; Yu, A; Sinclair, S; Furlan, S; Bosinger, S; et al.
Journal of Clinical Oncology.
2021;
39:1865-1877.